Lexaria Bioscience Corp. (NASDAQ: LEXX) will soon begin a human clinical study, NIC-H22-1, to compare its DehydraTECH-nicotine pouch performance with that of existing brands such as ON! and Zyn, currently available in the U.S. “Animal testing has already demonstrated that DehydraTECH-nicotine can deliver peak nicotine performance to the bloodstream 10 to 20 times faster than the study’s controls,” a recent article reads. “Lexaria has long held that any form of inhaling chemical substances can be detrimental to health, and its DehydraTECH-nicotine aims to help vapers as well as smokers wean themselves off of those products, giving them relief from cravings while offering a safer nicotine alternative. ‘My father also died from lung cancer … so I am no fan [of smoking],’ CEO Chris Bunka told Forbes in 2019. ‘The fact that [DehydraTECH] is fast means that smokers might not be frustrated waiting for their nicotine experience to begin, the way they have been with traditional nicotine products such as gums and lozenges.’”
To view the full article, visit https://nnw.fm/G6m1p
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
New York, New York
NetworkNewsWire is part of the InvestorBrandNetwork